At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Trastuzumab emtansine, and 1 other intervention for Metastatic Breast Cancer. Completed, enrolled 202 participants across 68 sites in 9 countries.
Detailed Summary
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC who have received prior trastuzumab and taxane based therapy, either alone or in combination, and/or who have progressed within 6 months after completing adjuvant therapy.
Study Details
Timeline
Interventions
Atezolizumab 1200 mg IV infusion
Trastuzumab emtansine 3.6 mg/kg IV infusion
Placebo matched to atezolizumab